Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
November 22 2017 - 4:05PM
YASTEST
DUBLIN, Ireland, Nov. 22, 2017
(GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a
late-stage clinical biotechnology company focused on the discovery,
development and commercialization of novel therapies in the
neuroscience and orphan arenas, today announced that members of its
senior management team will present and participate in the Evercore
ISI Biopharma Catalyst/Deep Dive Conference on November
30th at 1:15 PM ET in Boston, MA.
A live webcast of the company
presentation can be accessed through the investor relations section
of the Company's website at www.prothena.com. Following the live
presentation, a replay of the webcast will be available on the
Company's website for at least 90 days following the presentation
date.
About
Prothena
Prothena Corporation plc is a
global, late-stage clinical biotechnology company establishing
fully integrated research, development and commercial capabilities
and focused on advancing new therapies in the neuroscience and
orphan arenas. Fueled by its deep scientific understanding built
over decades of research in protein misfolding, Prothena seeks to
fundamentally change the course of grave or currently untreatable
diseases associated with this biology. Prothena's pipeline of
antibody therapeutic candidates targets a number of indications
including AL amyloidosis (NEOD001), Parkinson's disease and other
related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis
(PRX004). The Company continues discovery of additional novel
therapeutic candidates where its deep scientific understanding of
disease pathology can be leveraged. For more information, please
visit the Company's website at www.prothena.com.
Media &
Investor Contact:
Ellen Rose, Head of
Communications
650-922-2405, ellen.rose@prothena.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Prothena Corporation plc via Globenewswire
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Apr 2023 to Apr 2024